Oral Anti-diabetes Drugs Market : Size, Application Analysis, Regional Outlook, 2017 - 2025

Diabetes is a chronic disease that occurs when the body cannot effectively use the produced insulin or the pancreas does not produce sufficient insulin. The pancreas is an organ that sits behind the stomach and releases hormones into the digestive system. Diabetes is categorized by increased levels of blood glucose, which can cause severe damage to blood vessels, heart, kidneys, nerves, and eyes.

Diabetes is also called hyperglycemia or raised blood sugar. Insulin is a hormone that regulates the blood sugar level in body. Continuous increase in blood sugar leads to diabetes. Uncontrollable diabetes can damage the nervous system and other body systems.

Read Report Overview:https://www.transparencymarketresearch.com/oral-anti-diabetes-drugs-market.html

Diabetes is of two types: type 1 and type 2. Type 1 diabetes, also known as juvenile diabetes or insulin-dependent diabetes, arises when the immune system misguidedly attacks and kills the beta cells of the pancreas. In type 1 diabetes, little or no insulin is released into the body, owing to this sugar builds up in the blood instead of being used as energy. Type 1 diabetes is rare, and only 10% of people with diabetes have type 1 diabetes. It commonly occurs in childhood or adolescence. Type 2 diabetes arises when the body cannot appropriately use the insulin that is released or does not make enough insulin. As a consequence, sugar builds up in the blood instead of being used as energy. About 90% of people with diabetes have type 2 diabetes.

Oral Anti-diabetes Drugs Market: Dynamics

Increasing obese population and changing lifestyle are the factors projected to boost market growth. Advancements in technologies and reimbursement for medicines are anticipated to fuel the growth of the oral anti-diabetes drug market in the next few years. Moreover, rising incidence of diabetes is expected to increase demand for oral anti-diabetes drugs. However, ongoing research on diabetic treatment and high market potential are expected to create opportunities in the oral anti-diabetes market in the near future.

Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=23162

Oral Anti-diabetes Drugs Market: Segmentation

Based on dosage type, the global oral anti-diabetes drugs market has been segmented into:

• Liquid
• Capsule
• Tablet

In terms of drug class, the global oral anti-diabetes drugs market has been segmented into:

• Sulfonylureas
• Meglitinides

• Gliclazide
• Glyburide
• Glimepiride
• Others

• Biguanides
• Metformin
• Repaglinide
• Nateglinide
• Others

• Biguanides
• Others

• Alpha-glycosidase inhibitors
• Voglibose
• Acarbose
• Others

Request For TOC : https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=23162

Based on distribution channel, the global oral anti-diabetes drugs market has been segmented into:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

In terms of drug class, the global oral anti-diabetes drug market has been segmented into five types: alpha-glucosidase inhibitors, meglitinides, sulfonylureas, biguanides, and others. The biguanides derivatives and sulphonylureas segments are expected to account for major shares of the global oral anti-diabetes drug market.

Oral Anti-diabetes Drugs Market: Region-wise Outlook

In terms of region, the global oral anti-diabetes drugs market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global oral anti-diabetes drugs market, followed by Europe, owing to the introduction of new products and presence of favorable government initiatives for oral anti-diabetes drugs in the region. Asia Pacific is expected to witness the fastest growth in the near future attributed to increase geriatric population in the region.

Oral Anti-diabetes Drugs Market: Key Players

Major players operating in the global oral anti-diabetes drugs market are Eli Lilly, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Merck, GlaxoSmithKline, Piramal Healthcare, Bristol-Myers Squibb, Bayer Healthcare, Dr. Reddy’s Laboratories Ltd, and Pfizer. Increasing competition among key players is expected to drive the global oral anti-diabetes drugs market during the forecast period.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Transparency Market Research (Tmr) is a U.S.-based provider of syndicated research, customized research, and consulting services.